KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to $94.4 million.

  • Rigel Pharmaceuticals' Total Current Liabilities rose 7381.06% to $94.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.4 million, marking a year-over-year increase of 7381.06%. This contributed to the annual value of $63.3 million for FY2024, which is 1883.34% up from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' Total Current Liabilities is $94.4 million, which was up 7381.06% from $86.6 million recorded in Q2 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Total Current Liabilities peaked at $94.4 million during Q3 2025, and registered a low of $44.0 million during Q2 2023.
  • Its 5-year average for Total Current Liabilities is $60.5 million, with a median of $59.2 million in 2022.
  • In the last 5 years, Rigel Pharmaceuticals' Total Current Liabilities crashed by 2314.39% in 2023 and then skyrocketed by 7381.06% in 2025.
  • Quarter analysis of 5 years shows Rigel Pharmaceuticals' Total Current Liabilities stood at $63.6 million in 2021, then grew by 2.61% to $65.2 million in 2022, then fell by 18.32% to $53.3 million in 2023, then increased by 18.83% to $63.3 million in 2024, then surged by 49.13% to $94.4 million in 2025.
  • Its Total Current Liabilities was $94.4 million in Q3 2025, compared to $86.6 million in Q2 2025 and $66.6 million in Q1 2025.